David R Epstein's Insider Trades & SAST Disclosures
David R Epstein's most recent trade in Tempus AI Inc. - Ordinary Shares - Class A was a trade of 990 Class A Common Stock done at an average price of $46.8 . Disclosure was reported to the exchange on March 17, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David R Epstein.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tempus AI Inc. - Ordinary ... | David R. Epstein | Director | Sale of securities on an exchange or to another person at price $ 46.83 per share. | 17 Mar 2025 | 990 | 26,284 | - | 46.8 | 46,362 | Class A Common Stock |
| Tempus AI Inc. - Ordinary ... | David R. Epstein | Director | Sale of securities on an exchange or to another person at price $ 57.52 per share. | 03 Mar 2025 | 250 | 27,274 | - | 57.5 | 14,380 | Class A Common Stock |
| Tempus AI Inc. - Ordinary ... | David R. Epstein | Director | Sale of securities on an exchange or to another person at price $ 53.31 per share. | 03 Feb 2025 | 370 | 27,524 | - | 53.3 | 19,725 | Class A Common Stock |
| Tempus AI Inc. - Ordinary ... | Epstein David R. | Director | Sale of securities on an exchange or to another person at price $ 41.81 per share. | 11 Dec 2024 | 620 | 27,894 | - | 41.8 | 25,922 | Class A Common Stock |
| Tempus AI Inc. - Ordinary ... | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 28,514 | 28,514 | - | 0 | Class A Common Stock | |
| Seagen Inc | David R. Epstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 39,650 | 147,218 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | David R. Epstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2022 | 400,000 | 400,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Seagen Inc | David R. Epstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2022 | 240,451 | 240,451 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Seagen Inc | David R. Epstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2022 | 107,389 | 107,389 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | David R. Epstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2022 | 2,896 | 2,896 | - | - | Incentive Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,874 | 0 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,874 | 93,932 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,053 | 0 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2022 | 2,053 | 91,058 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 112,519 | 123,252 | - | 0 | Common Stock | |
| Senti Biosciences Inc. | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 112,519 | 0 | - | - | Class B Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,873 | 89,005 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,873 | 2,874 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,052 | 2,053 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 2,052 | 86,132 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 1.46 per share. | 27 May 2022 | 17,123 | 84,080 (0%) | 0% | 1.5 | 25,000 | Common Stock |
| Axcella Health Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 47,059 | 209,756 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,873 | 5,747 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,873 | 66,957 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,053 | 64,084 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 2,053 | 4,105 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,874 | 8,620 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,874 | 62,031 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,052 | 59,157 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,052 | 6,158 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 1,535 | 0 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2022 | 1,535 | 162,697 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 16 Mar 2022 | 26,178 | 161,162 (0%) | 0% | 1.9 | 50,000 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,873 | 57,105 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,873 | 11,494 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,053 | 8,210 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 2,053 | 54,232 (0%) | 0% | 0 | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,534 | 134,984 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,534 | 1,535 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,873 | 52,179 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,873 | 14,367 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,052 | 49,306 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 2,052 | 10,263 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 1,535 | 3,069 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 1,535 | 133,450 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 1,535 | 4,604 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2021 | 1,535 | 131,915 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,873 | 20,114 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,873 | 42,328 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,053 | 39,455 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 2,053 | 14,367 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2021 | 1,534 | 6,139 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2021 | 1,534 | 130,380 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,873 | 37,402 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,873 | 22,987 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,052 | 16,420 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,052 | 34,529 (0%) | 0% | 0 | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2021 | 1,535 | 7,673 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2021 | 1,535 | 128,846 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,874 | 25,860 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,874 | 32,477 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,053 | 18,472 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,053 | 29,603 (0%) | 0% | 0 | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 1,535 | 9,208 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 1,535 | 127,311 (0%) | 0% | - | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 5,746 | 28,734 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 5,746 | 27,550 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 4,104 | 21,804 (0%) | 0% | 0 | Common Stock | |
| Evelo Biosciences Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 4,104 | 20,525 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2021 | 1,534 | 10,743 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2021 | 1,534 | 125,776 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2021 | 1,535 | 124,242 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2021 | 1,535 | 12,277 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 34,480 | 34,480 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 24,629 | 24,629 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 1,535 | 122,707 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2021 | 1,535 | 13,812 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 1,534 | 15,347 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 1,534 | 121,172 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2021 | 1,535 | 16,881 | - | - | Restricted Stock Units | |
| Axcella Health Inc | David R. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2021 | 1,535 | 119,638 (0%) | 0% | - | Common Stock | |
| Axcella Health Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Axcella Health Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 18,416 | 18,416 | - | - | Restricted Stock Units | |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.49 per share. | 11 Dec 2020 | 4,970 | 15,200 (0%) | 0% | 6.5 | 32,255 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.91 per share. | 11 Dec 2020 | 1,000 | 17,000 (0%) | 0% | 6.9 | 6,910 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 7.16 per share. | 11 Dec 2020 | 800 | 16,000 (0%) | 0% | 7.2 | 5,728 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.98 per share. | 11 Dec 2020 | 500 | 17,500 (0%) | 0% | 7.0 | 3,490 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.40 per share. | 11 Dec 2020 | 200 | 10,200 (0%) | 0% | 6.4 | 1,280 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 7.02 per share. | 11 Dec 2020 | 200 | 17,700 (0%) | 0% | 7.0 | 1,404 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 6.47 per share. | 11 Dec 2020 | 30 | 10,230 (0%) | 0% | 6.5 | 194 | Common Stock |
| International Flavors & Fr... | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2020 | 1,070 | 6,397 | - | - | Stock Equivalent Unit | |
| Evelo Biosciences Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2020 | 59,395 | 59,395 | - | - | Stock Option (Right to Buy) | |
| Evelo Biosciences Inc | David R. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2020 | 44,743 | 44,743 | - | - | Stock Option (Right to Buy) | |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.40 per share. | 28 Aug 2020 | 3,248 | 4,248 (0%) | 0% | 4.4 | 14,291 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.46 per share. | 28 Aug 2020 | 2,752 | 7,000 (0%) | 0% | 4.5 | 12,274 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.34 per share. | 28 Aug 2020 | 1,000 | 1,000 (0%) | 0% | 4.3 | 4,340 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.47 per share. | 28 Aug 2020 | 1,000 | 8,000 (0%) | 0% | 4.5 | 4,470 | Common Stock |
| Evelo Biosciences Inc | David R. Epstein | Director | Purchase of securities on an exchange or from another person at price $ 4.48 per share. | 28 Aug 2020 | 1,000 | 9,000 (0%) | 0% | 4.5 | 4,480 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges